TransStem – University of Copenhagen

Forward this page to a friend Resize Print Bookmark and Share

DanStem > Research > TransStem

TransStem research group

The Section for Strategic Translational Stem Cell Research and Therapy (TransStem) is focused on the translation of promising basic research results into new strategies and targets for the development of new therapies for cancer and diabetes. The aim is to move these fields towards early clinical application.

The group top priorities include:

  • Development of a safe and efficient therapy for diabetes based on human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs), including development of scalable differentiation protocols for functional insulin-producing beta cells.
  • Establishment of human iPSC-based in vitro models for inherited forms of diabetes.
  • Identification and validation of novel targets for anti-cancer therapy.
  • Development of novel lead compounds for anti-cancer therapy in collaboration with industry.

TransStem Principal Investigators, research groups and industry partners:

Professor Henrik Semb DanStem (Head)
Professor Kristian Helin DanStem/BRIC
Professor Bo Porse DanStem/The Finsen Laboratory and BRIC
Professor Ole William Petersen DanStem/ICMM
Chief Physician Kirsten Grønbæk Senior Researcher, Rigshospitalet
Professor Olle Korsgren Uppsala University (SE)
Director of Beta Cell Biology Ole Dragsbæk Madsen Hagedorn, Novo Nordisk A/S

Cancer Stem Cells research groups

  The Helin Laboratory investigates the mechanisms that regulate cell-fate decisions in stem cells, differentiated cells as well as tumor cells with the aim of gaining new insights into the molecular mechanisms leading to cancer ... read more

  The Petersen Laboratory focuses on morphogenesis and differentiation of normal and neoplastic human breast tissue... read more

  The Porse Laboratory focuses on the role of transcription factors in normal and malignant hematopoiesis and nonsense-mediated mRNA decay (NMD) in vivo... read more